Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2015 - 2026)

Corvus Pharmaceuticals' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 183.23% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$30.5 million (down 11.09% YoY), while the FY2025 annual figure was -$102.1 million, down 12.78% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$13.1 million, down from -$9.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was $15.7 million in Q1 2025, with the low at -$39.5 million in Q3 2024.
• The 5-year median for Income towards Parent Company is -$6.1 million (2023), against an average of -$8.0 million.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 669.91% in 2024, then jumped 364.98% in 2025.
• Corvus Pharmaceuticals' Income towards Parent Company stood at -$5.8 million in 2022, then gained by 0.8% to -$5.7 million in 2023, then plunged by 589.72% to -$39.5 million in 2024, then surged by 75.13% to -$9.8 million in 2025, then plunged by 33.14% to -$13.1 million in 2026.
• Business Quant data shows CRVS's Income towards Parent Company at -$13.1 million in Q1 2026, -$9.8 million in Q3 2025, and -$7.6 million in Q2 2025.